id	sid	tid	token	lemma	pos
cord-028530-hpgrbhkl	1	1	key	key	JJ
cord-028530-hpgrbhkl	1	2	:	:	:
cord-028530-hpgrbhkl	1	3	cord-028530-hpgrbhkl	cord-028530-hpgrbhkl	ADD
cord-028530-hpgrbhkl	2	1	authors	author	NNS
cord-028530-hpgrbhkl	2	2	:	:	:
cord-028530-hpgrbhkl	2	3	Cairoli	Cairoli	NNP
cord-028530-hpgrbhkl	2	4	,	,	,
cord-028530-hpgrbhkl	2	5	Ernesto	Ernesto	NNP
cord-028530-hpgrbhkl	2	6	;	;	:
cord-028530-hpgrbhkl	2	7	Espinosa	Espinosa	NNP
cord-028530-hpgrbhkl	2	8	,	,	,
cord-028530-hpgrbhkl	3	1	Gerard	Gerard	NNP
cord-028530-hpgrbhkl	3	2	title	title	NN
cord-028530-hpgrbhkl	3	3	:	:	:
cord-028530-hpgrbhkl	3	4	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-028530-hpgrbhkl	3	5	in	in	IN
cord-028530-hpgrbhkl	3	6	the	the	DT
cord-028530-hpgrbhkl	3	7	treatment	treatment	NN
cord-028530-hpgrbhkl	3	8	of	of	IN
cord-028530-hpgrbhkl	3	9	COVID-19	covid-19	NN
cord-028530-hpgrbhkl	3	10	:	:	:
cord-028530-hpgrbhkl	4	1	how	how	WRB
cord-028530-hpgrbhkl	4	2	to	to	TO
cord-028530-hpgrbhkl	4	3	use	use	VB
cord-028530-hpgrbhkl	4	4	it	-PRON-	PRP
cord-028530-hpgrbhkl	4	5	waiting	wait	VBG
cord-028530-hpgrbhkl	4	6	for	for	IN
cord-028530-hpgrbhkl	4	7	conclusive	conclusive	JJ
cord-028530-hpgrbhkl	4	8	scientific	scientific	JJ
cord-028530-hpgrbhkl	4	9	evidence	evidence	NN
cord-028530-hpgrbhkl	4	10	(	(	-LRB-
cord-028530-hpgrbhkl	4	11	)	)	-RRB-
cord-028530-hpgrbhkl	4	12	date	date	NN
cord-028530-hpgrbhkl	4	13	:	:	:
cord-028530-hpgrbhkl	4	14	2020	2020	CD
cord-028530-hpgrbhkl	4	15	-	-	HYPH
cord-028530-hpgrbhkl	4	16	07	07	CD
cord-028530-hpgrbhkl	4	17	-	-	HYPH
cord-028530-hpgrbhkl	4	18	04	04	CD
cord-028530-hpgrbhkl	4	19	journal	journal	NN
cord-028530-hpgrbhkl	4	20	:	:	:
cord-028530-hpgrbhkl	5	1	Med	Med	NNP
cord-028530-hpgrbhkl	5	2	Clin	Clin	NNP
cord-028530-hpgrbhkl	5	3	(	(	-LRB-
cord-028530-hpgrbhkl	5	4	Engl	Engl	NNP
cord-028530-hpgrbhkl	5	5	Ed	Ed	NNP
cord-028530-hpgrbhkl	5	6	)	)	-RRB-
cord-028530-hpgrbhkl	5	7	DOI	DOI	NNP
cord-028530-hpgrbhkl	5	8	:	:	:
cord-028530-hpgrbhkl	5	9	10.1016/	10.1016/	CD
cord-028530-hpgrbhkl	6	1	j.medcle.2020.05.003	j.medcle.2020.05.003	NNP
cord-028530-hpgrbhkl	6	2	sha	sha	NNP
cord-028530-hpgrbhkl	6	3	:	:	:
cord-028530-hpgrbhkl	6	4	80b833e0eb1e15eaeb77ce67470d0ddb502e7cdf	80b833e0eb1e15eaeb77ce67470d0ddb502e7cdf	CD
cord-028530-hpgrbhkl	6	5	doc_id	doc_id	CD
cord-028530-hpgrbhkl	6	6	:	:	:
cord-028530-hpgrbhkl	6	7	28530	28530	CD
cord-028530-hpgrbhkl	6	8	cord_uid	cord_uid	NNS
cord-028530-hpgrbhkl	6	9	:	:	:
cord-028530-hpgrbhkl	6	10	hpgrbhkl	hpgrbhkl	NNP
cord-028530-hpgrbhkl	7	1	nan	nan	NNP
cord-028530-hpgrbhkl	7	2	Letter	Letter	NNP
cord-028530-hpgrbhkl	7	3	to	to	IN
cord-028530-hpgrbhkl	7	4	the	the	DT
cord-028530-hpgrbhkl	7	5	Editor	Editor	NNP
cord-028530-hpgrbhkl	7	6	Hidroxicloroquina	Hidroxicloroquina	NNP
cord-028530-hpgrbhkl	7	7	en	en	IN
cord-028530-hpgrbhkl	7	8	el	el	NNP
cord-028530-hpgrbhkl	7	9	tratamiento	tratamiento	NNP
cord-028530-hpgrbhkl	7	10	del	del	NNP
cord-028530-hpgrbhkl	8	1	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	8	2	:	:	:
cord-028530-hpgrbhkl	8	3	como	como	NNP
cord-028530-hpgrbhkl	8	4	utilizarla	utilizarla	NNP
cord-028530-hpgrbhkl	8	5	a	a	NNP
cord-028530-hpgrbhkl	8	6	la	la	FW
cord-028530-hpgrbhkl	8	7	espera	espera	FW
cord-028530-hpgrbhkl	8	8	de	de	FW
cord-028530-hpgrbhkl	8	9	evidencia	evidencia	NNP
cord-028530-hpgrbhkl	8	10	científica	científica	NNP
cord-028530-hpgrbhkl	8	11	concluyente	concluyente	NNP
cord-028530-hpgrbhkl	8	12	.	.	.
cord-028530-hpgrbhkl	9	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-028530-hpgrbhkl	9	2	in	in	IN
cord-028530-hpgrbhkl	9	3	the	the	DT
cord-028530-hpgrbhkl	9	4	treatment	treatment	NN
cord-028530-hpgrbhkl	9	5	of	of	IN
cord-028530-hpgrbhkl	9	6	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	9	7	:	:	:
cord-028530-hpgrbhkl	9	8	how	how	WRB
cord-028530-hpgrbhkl	9	9	to	to	TO
cord-028530-hpgrbhkl	9	10	use	use	VB
cord-028530-hpgrbhkl	9	11	it	-PRON-	PRP
cord-028530-hpgrbhkl	9	12	waiting	wait	VBG
cord-028530-hpgrbhkl	9	13	for	for	IN
cord-028530-hpgrbhkl	9	14	conclusive	conclusive	JJ
cord-028530-hpgrbhkl	9	15	scientific	scientific	JJ
cord-028530-hpgrbhkl	9	16	evidence	evidence	NN
cord-028530-hpgrbhkl	10	1	Autores	autore	NNS
cord-028530-hpgrbhkl	10	2	:	:	:
cord-028530-hpgrbhkl	10	3	Ernesto	Ernesto	NNP
cord-028530-hpgrbhkl	10	4	Cairoli	Cairoli	NNP
cord-028530-hpgrbhkl	10	5	MD	MD	NNP
cord-028530-hpgrbhkl	10	6	,	,	,
cord-028530-hpgrbhkl	10	7	PhD	PhD	NNP
cord-028530-hpgrbhkl	10	8	a	a	NNP
cord-028530-hpgrbhkl	10	9	,	,	,
cord-028530-hpgrbhkl	10	10	b	b	NN
cord-028530-hpgrbhkl	10	11	,	,	,
cord-028530-hpgrbhkl	10	12	Gerard	Gerard	NNP
cord-028530-hpgrbhkl	10	13	Espinosa	Espinosa	NNP
cord-028530-hpgrbhkl	10	14	MD	MD	NNP
cord-028530-hpgrbhkl	10	15	,	,	,
cord-028530-hpgrbhkl	10	16	PhD	PhD	NNP
cord-028530-hpgrbhkl	10	17	c	c	NNP
cord-028530-hpgrbhkl	10	18	.	.	.
cord-028530-hpgrbhkl	10	19	 	 	_SP
cord-028530-hpgrbhkl	11	1	To	to	IN
cord-028530-hpgrbhkl	11	2	date	date	NN
cord-028530-hpgrbhkl	11	3	,	,	,
cord-028530-hpgrbhkl	11	4	there	there	EX
cord-028530-hpgrbhkl	11	5	is	be	VBZ
cord-028530-hpgrbhkl	11	6	no	no	DT
cord-028530-hpgrbhkl	11	7	effective	effective	JJ
cord-028530-hpgrbhkl	11	8	treatment	treatment	NN
cord-028530-hpgrbhkl	11	9	against	against	IN
cord-028530-hpgrbhkl	11	10	the	the	DT
cord-028530-hpgrbhkl	11	11	novel	novel	JJ
cord-028530-hpgrbhkl	11	12	severe	severe	JJ
cord-028530-hpgrbhkl	11	13	acute	acute	JJ
cord-028530-hpgrbhkl	11	14	respiratory	respiratory	JJ
cord-028530-hpgrbhkl	11	15	syndrome	syndrome	NN
cord-028530-hpgrbhkl	11	16	coronavirus	coronavirus	NN
cord-028530-hpgrbhkl	11	17	2	2	CD
cord-028530-hpgrbhkl	11	18	(	(	-LRB-
cord-028530-hpgrbhkl	11	19	SARS	SARS	NNP
cord-028530-hpgrbhkl	11	20	-	-	HYPH
cord-028530-hpgrbhkl	11	21	CoV-2	CoV-2	NNP
cord-028530-hpgrbhkl	11	22	)	)	-RRB-
cord-028530-hpgrbhkl	11	23	,	,	,
cord-028530-hpgrbhkl	11	24	responsible	responsible	JJ
cord-028530-hpgrbhkl	11	25	for	for	IN
cord-028530-hpgrbhkl	11	26	the	the	DT
cord-028530-hpgrbhkl	11	27	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	11	28	disease	disease	NN
cord-028530-hpgrbhkl	11	29	.	.	.
cord-028530-hpgrbhkl	12	1	Numerous	numerous	JJ
cord-028530-hpgrbhkl	12	2	clinical	clinical	JJ
cord-028530-hpgrbhkl	12	3	studies	study	NNS
cord-028530-hpgrbhkl	12	4	are	be	VBP
cord-028530-hpgrbhkl	12	5	evaluating	evaluate	VBG
cord-028530-hpgrbhkl	12	6	the	the	DT
cord-028530-hpgrbhkl	12	7	utility	utility	NN
cord-028530-hpgrbhkl	12	8	of	of	IN
cord-028530-hpgrbhkl	12	9	antiviral	antiviral	JJ
cord-028530-hpgrbhkl	12	10	and	and	CC
cord-028530-hpgrbhkl	12	11	immunomodulatory	immunomodulatory	JJ
cord-028530-hpgrbhkl	12	12	drugs	drug	NNS
cord-028530-hpgrbhkl	12	13	,	,	,
cord-028530-hpgrbhkl	12	14	where	where	WRB
cord-028530-hpgrbhkl	12	15	antimalarials	antimalarial	NNS
cord-028530-hpgrbhkl	12	16	such	such	JJ
cord-028530-hpgrbhkl	12	17	as	as	IN
cord-028530-hpgrbhkl	12	18	chloroquine	chloroquine	NNP
cord-028530-hpgrbhkl	12	19	and	and	CC
cord-028530-hpgrbhkl	12	20	hydroxychloroquine	hydroxychloroquine	NNP
cord-028530-hpgrbhkl	12	21	(	(	-LRB-
cord-028530-hpgrbhkl	12	22	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	12	23	)	)	-RRB-
cord-028530-hpgrbhkl	12	24	are	be	VBP
cord-028530-hpgrbhkl	12	25	one	one	CD
cord-028530-hpgrbhkl	12	26	of	of	IN
cord-028530-hpgrbhkl	12	27	the	the	DT
cord-028530-hpgrbhkl	12	28	alternatives	alternative	NNS
cord-028530-hpgrbhkl	12	29	studied	study	VBD
cord-028530-hpgrbhkl	12	30	1	1	CD
cord-028530-hpgrbhkl	12	31	.	.	.
cord-028530-hpgrbhkl	13	1	So	so	RB
cord-028530-hpgrbhkl	13	2	far	far	RB
cord-028530-hpgrbhkl	13	3	,	,	,
cord-028530-hpgrbhkl	13	4	clinical	clinical	JJ
cord-028530-hpgrbhkl	13	5	experience	experience	NN
cord-028530-hpgrbhkl	13	6	in	in	IN
cord-028530-hpgrbhkl	13	7	the	the	DT
cord-028530-hpgrbhkl	13	8	use	use	NN
cord-028530-hpgrbhkl	13	9	of	of	IN
cord-028530-hpgrbhkl	13	10	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	13	11	arises	arise	VBZ
cord-028530-hpgrbhkl	13	12	mainly	mainly	RB
cord-028530-hpgrbhkl	13	13	from	from	IN
cord-028530-hpgrbhkl	13	14	treatment	treatment	NN
cord-028530-hpgrbhkl	13	15	in	in	IN
cord-028530-hpgrbhkl	13	16	patients	patient	NNS
cord-028530-hpgrbhkl	13	17	with	with	IN
cord-028530-hpgrbhkl	13	18	systemic	systemic	JJ
cord-028530-hpgrbhkl	13	19	lupus	lupus	NN
cord-028530-hpgrbhkl	13	20	erythematosus	erythematosus	NN
cord-028530-hpgrbhkl	13	21	(	(	-LRB-
cord-028530-hpgrbhkl	13	22	SLE	SLE	NNP
cord-028530-hpgrbhkl	13	23	)	)	-RRB-
cord-028530-hpgrbhkl	13	24	,	,	,
cord-028530-hpgrbhkl	13	25	whose	whose	WP$
cord-028530-hpgrbhkl	13	26	long	long	JJ
cord-028530-hpgrbhkl	13	27	-	-	HYPH
cord-028530-hpgrbhkl	13	28	term	term	NN
cord-028530-hpgrbhkl	13	29	effects	effect	NNS
cord-028530-hpgrbhkl	13	30	show	show	VBP
cord-028530-hpgrbhkl	13	31	multiple	multiple	JJ
cord-028530-hpgrbhkl	13	32	benefits	benefit	NNS
cord-028530-hpgrbhkl	13	33	.	.	.
cord-028530-hpgrbhkl	14	1	However	however	RB
cord-028530-hpgrbhkl	14	2	,	,	,
cord-028530-hpgrbhkl	14	3	high	high	JJ
cord-028530-hpgrbhkl	14	4	cumulative	cumulative	JJ
cord-028530-hpgrbhkl	14	5	doses	dose	NNS
cord-028530-hpgrbhkl	14	6	have	have	VBP
cord-028530-hpgrbhkl	14	7	been	be	VBN
cord-028530-hpgrbhkl	14	8	associated	associate	VBN
cord-028530-hpgrbhkl	14	9	with	with	IN
cord-028530-hpgrbhkl	14	10	serious	serious	JJ
cord-028530-hpgrbhkl	14	11	adverse	adverse	JJ
cord-028530-hpgrbhkl	14	12	effects	effect	NNS
cord-028530-hpgrbhkl	14	13	,	,	,
cord-028530-hpgrbhkl	14	14	especially	especially	RB
cord-028530-hpgrbhkl	14	15	in	in	IN
cord-028530-hpgrbhkl	14	16	the	the	DT
cord-028530-hpgrbhkl	14	17	retina	retina	NN
cord-028530-hpgrbhkl	14	18	and	and	CC
cord-028530-hpgrbhkl	14	19	myocardium	myocardium	NN
cord-028530-hpgrbhkl	14	20	2	2	CD
cord-028530-hpgrbhkl	14	21	.	.	.
cord-028530-hpgrbhkl	15	1	Many	many	JJ
cord-028530-hpgrbhkl	15	2	healthcare	healthcare	NN
cord-028530-hpgrbhkl	15	3	protocols	protocol	NNS
cord-028530-hpgrbhkl	15	4	propose	propose	VBP
cord-028530-hpgrbhkl	15	5	the	the	DT
cord-028530-hpgrbhkl	15	6	use	use	NN
cord-028530-hpgrbhkl	15	7	of	of	IN
cord-028530-hpgrbhkl	15	8	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	15	9	in	in	IN
cord-028530-hpgrbhkl	15	10	the	the	DT
cord-028530-hpgrbhkl	15	11	treatment	treatment	NN
cord-028530-hpgrbhkl	15	12	of	of	IN
cord-028530-hpgrbhkl	15	13	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	15	14	1	1	CD
cord-028530-hpgrbhkl	15	15	.	.	.
cord-028530-hpgrbhkl	16	1	However	however	RB
cord-028530-hpgrbhkl	16	2	,	,	,
cord-028530-hpgrbhkl	16	3	it	-PRON-	PRP
cord-028530-hpgrbhkl	16	4	is	be	VBZ
cord-028530-hpgrbhkl	16	5	important	important	JJ
cord-028530-hpgrbhkl	16	6	to	to	TO
cord-028530-hpgrbhkl	16	7	consider	consider	VB
cord-028530-hpgrbhkl	16	8	adverse	adverse	JJ
cord-028530-hpgrbhkl	16	9	myocardial	myocardial	JJ
cord-028530-hpgrbhkl	16	10	effects	effect	NNS
cord-028530-hpgrbhkl	16	11	,	,	,
cord-028530-hpgrbhkl	16	12	such	such	JJ
cord-028530-hpgrbhkl	16	13	as	as	IN
cord-028530-hpgrbhkl	16	14	the	the	DT
cord-028530-hpgrbhkl	16	15	development	development	NN
cord-028530-hpgrbhkl	16	16	of	of	IN
cord-028530-hpgrbhkl	16	17	severe	severe	JJ
cord-028530-hpgrbhkl	16	18	arrhythmias	arrhythmia	NNS
cord-028530-hpgrbhkl	16	19	3	3	CD
cord-028530-hpgrbhkl	16	20	,	,	,
cord-028530-hpgrbhkl	16	21	4	4	CD
cord-028530-hpgrbhkl	16	22	.	.	.
cord-028530-hpgrbhkl	17	1	In	in	IN
cord-028530-hpgrbhkl	17	2	the	the	DT
cord-028530-hpgrbhkl	17	3	COVID-19	covid-19	JJ
cord-028530-hpgrbhkl	17	4	patient	patient	NN
cord-028530-hpgrbhkl	17	5	,	,	,
cord-028530-hpgrbhkl	17	6	possible	possible	JJ
cord-028530-hpgrbhkl	17	7	cardiac	cardiac	JJ
cord-028530-hpgrbhkl	17	8	involvement	involvement	NN
cord-028530-hpgrbhkl	17	9	is	be	VBZ
cord-028530-hpgrbhkl	17	10	mainly	mainly	RB
cord-028530-hpgrbhkl	17	11	related	relate	VBN
cord-028530-hpgrbhkl	17	12	to	to	IN
cord-028530-hpgrbhkl	17	13	4	4	CD
cord-028530-hpgrbhkl	17	14	factors	factor	NNS
cord-028530-hpgrbhkl	17	15	:	:	:
cord-028530-hpgrbhkl	17	16	1	1	LS
cord-028530-hpgrbhkl	17	17	)	)	-RRB-
cord-028530-hpgrbhkl	17	18	underlying	underlie	VBG
cord-028530-hpgrbhkl	17	19	heart	heart	NN
cord-028530-hpgrbhkl	17	20	disease	disease	NN
cord-028530-hpgrbhkl	17	21	(	(	-LRB-
cord-028530-hpgrbhkl	17	22	often	often	RB
cord-028530-hpgrbhkl	17	23	silent	silent	JJ
cord-028530-hpgrbhkl	17	24	in	in	IN
cord-028530-hpgrbhkl	17	25	older	old	JJR
cord-028530-hpgrbhkl	17	26	patients	patient	NNS
cord-028530-hpgrbhkl	17	27	)	)	-RRB-
cord-028530-hpgrbhkl	17	28	;	;	:
cord-028530-hpgrbhkl	17	29	2	2	LS
cord-028530-hpgrbhkl	17	30	)	)	-RRB-
cord-028530-hpgrbhkl	17	31	myocardial	myocardial	JJ
cord-028530-hpgrbhkl	17	32	involvement	involvement	NN
cord-028530-hpgrbhkl	17	33	caused	cause	VBN
cord-028530-hpgrbhkl	17	34	by	by	IN
cord-028530-hpgrbhkl	17	35	the	the	DT
cord-028530-hpgrbhkl	17	36	infection	infection	NN
cord-028530-hpgrbhkl	17	37	and	and	CC
cord-028530-hpgrbhkl	17	38	the	the	DT
cord-028530-hpgrbhkl	17	39	inflammatory	inflammatory	JJ
cord-028530-hpgrbhkl	17	40	response	response	NN
cord-028530-hpgrbhkl	17	41	itself	-PRON-	PRP
cord-028530-hpgrbhkl	17	42	,	,	,
cord-028530-hpgrbhkl	17	43	which	which	WDT
cord-028530-hpgrbhkl	17	44	leads	lead	VBZ
cord-028530-hpgrbhkl	17	45	to	to	TO
cord-028530-hpgrbhkl	17	46	myocarditis	myocarditis	VB
cord-028530-hpgrbhkl	17	47	with	with	IN
cord-028530-hpgrbhkl	17	48	elevated	elevated	JJ
cord-028530-hpgrbhkl	17	49	troponins	troponin	NNS
cord-028530-hpgrbhkl	17	50	;	;	:
cord-028530-hpgrbhkl	17	51	3	3	LS
cord-028530-hpgrbhkl	17	52	)	)	-RRB-
cord-028530-hpgrbhkl	17	53	acute	acute	JJ
cord-028530-hpgrbhkl	17	54	toxicity	toxicity	NN
cord-028530-hpgrbhkl	17	55	probably	probably	RB
cord-028530-hpgrbhkl	17	56	associated	associate	VBD
cord-028530-hpgrbhkl	17	57	with	with	IN
cord-028530-hpgrbhkl	17	58	the	the	DT
cord-028530-hpgrbhkl	17	59	use	use	NN
cord-028530-hpgrbhkl	17	60	of	of	IN
cord-028530-hpgrbhkl	17	61	antimalarials	antimalarial	NNS
cord-028530-hpgrbhkl	17	62	in	in	IN
cord-028530-hpgrbhkl	17	63	high	high	JJ
cord-028530-hpgrbhkl	17	64	doses	dose	NNS
cord-028530-hpgrbhkl	17	65	,	,	,
cord-028530-hpgrbhkl	17	66	more	more	RBR
cord-028530-hpgrbhkl	17	67	evident	evident	JJ
cord-028530-hpgrbhkl	17	68	in	in	IN
cord-028530-hpgrbhkl	17	69	chloroquine	chloroquine	NN
cord-028530-hpgrbhkl	17	70	treatments	treatment	NNS
cord-028530-hpgrbhkl	17	71	and	and	CC
cord-028530-hpgrbhkl	17	72	4	4	CD
cord-028530-hpgrbhkl	17	73	)	)	-RRB-
cord-028530-hpgrbhkl	17	74	concomitant	concomitant	JJ
cord-028530-hpgrbhkl	17	75	use	use	NN
cord-028530-hpgrbhkl	17	76	of	of	IN
cord-028530-hpgrbhkl	17	77	other	other	JJ
cord-028530-hpgrbhkl	17	78	treatments	treatment	NNS
cord-028530-hpgrbhkl	17	79	that	that	WDT
cord-028530-hpgrbhkl	17	80	,	,	,
cord-028530-hpgrbhkl	17	81	together	together	RB
cord-028530-hpgrbhkl	17	82	with	with	IN
cord-028530-hpgrbhkl	17	83	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	17	84	,	,	,
cord-028530-hpgrbhkl	17	85	prolong	prolong	VB
cord-028530-hpgrbhkl	17	86	the	the	DT
cord-028530-hpgrbhkl	17	87	corrected	correct	VBN
cord-028530-hpgrbhkl	17	88	QT	qt	NN
cord-028530-hpgrbhkl	17	89	interval	interval	NN
cord-028530-hpgrbhkl	17	90	(	(	-LRB-
cord-028530-hpgrbhkl	17	91	QTc	QTc	NNP
cord-028530-hpgrbhkl	17	92	)	)	-RRB-
cord-028530-hpgrbhkl	17	93	,	,	,
cord-028530-hpgrbhkl	17	94	with	with	IN
cord-028530-hpgrbhkl	17	95	the	the	DT
cord-028530-hpgrbhkl	17	96	risk	risk	NN
cord-028530-hpgrbhkl	17	97	of	of	IN
cord-028530-hpgrbhkl	17	98	serious	serious	JJ
cord-028530-hpgrbhkl	17	99	ventricular	ventricular	JJ
cord-028530-hpgrbhkl	17	100	arrhythmias	arrhythmias	RB
cord-028530-hpgrbhkl	17	101	3	3	CD
cord-028530-hpgrbhkl	17	102	-	-	SYM
cord-028530-hpgrbhkl	17	103	5	5	CD
cord-028530-hpgrbhkl	17	104	.	.	.
cord-028530-hpgrbhkl	18	1	In	in	IN
cord-028530-hpgrbhkl	18	2	the	the	DT
cord-028530-hpgrbhkl	18	3	absence	absence	NN
cord-028530-hpgrbhkl	18	4	(	(	-LRB-
cord-028530-hpgrbhkl	18	5	pending	pende	VBG
cord-028530-hpgrbhkl	18	6	)	)	-RRB-
cord-028530-hpgrbhkl	18	7	of	of	IN
cord-028530-hpgrbhkl	18	8	conclusive	conclusive	JJ
cord-028530-hpgrbhkl	18	9	scientific	scientific	JJ
cord-028530-hpgrbhkl	18	10	evidence	evidence	NN
cord-028530-hpgrbhkl	18	11	,	,	,
cord-028530-hpgrbhkl	18	12	what	what	WDT
cord-028530-hpgrbhkl	18	13	considerations	consideration	NNS
cord-028530-hpgrbhkl	18	14	should	should	MD
cord-028530-hpgrbhkl	18	15	be	be	VB
cord-028530-hpgrbhkl	18	16	taken	take	VBN
cord-028530-hpgrbhkl	18	17	into	into	IN
cord-028530-hpgrbhkl	18	18	account	account	NN
cord-028530-hpgrbhkl	18	19	when	when	WRB
cord-028530-hpgrbhkl	18	20	using	use	VBG
cord-028530-hpgrbhkl	18	21	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	18	22	in	in	IN
cord-028530-hpgrbhkl	18	23	the	the	DT
cord-028530-hpgrbhkl	18	24	treatment	treatment	NN
cord-028530-hpgrbhkl	18	25	of	of	IN
cord-028530-hpgrbhkl	18	26	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	18	27	?	?	.
cord-028530-hpgrbhkl	19	1	It	-PRON-	PRP
cord-028530-hpgrbhkl	19	2	is	be	VBZ
cord-028530-hpgrbhkl	19	3	necessary	necessary	JJ
cord-028530-hpgrbhkl	19	4	to	to	TO
cord-028530-hpgrbhkl	19	5	change	change	VB
cord-028530-hpgrbhkl	19	6	the	the	DT
cord-028530-hpgrbhkl	19	7	way	way	NN
cord-028530-hpgrbhkl	19	8	in	in	IN
cord-028530-hpgrbhkl	19	9	which	which	WDT
cord-028530-hpgrbhkl	19	10	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	19	11	is	be	VBZ
cord-028530-hpgrbhkl	19	12	usually	usually	RB
cord-028530-hpgrbhkl	19	13	used	use	VBN
cord-028530-hpgrbhkl	19	14	in	in	IN
cord-028530-hpgrbhkl	19	15	patients	patient	NNS
cord-028530-hpgrbhkl	19	16	with	with	IN
cord-028530-hpgrbhkl	19	17	SLE	SLE	NNP
cord-028530-hpgrbhkl	19	18	,	,	,
cord-028530-hpgrbhkl	19	19	adapting	adapt	VBG
cord-028530-hpgrbhkl	19	20	its	-PRON-	PRP$
cord-028530-hpgrbhkl	19	21	prescription	prescription	NN
cord-028530-hpgrbhkl	19	22	and	and	CC
cord-028530-hpgrbhkl	19	23	control	control	NN
cord-028530-hpgrbhkl	19	24	of	of	IN
cord-028530-hpgrbhkl	19	25	potential	potential	JJ
cord-028530-hpgrbhkl	19	26	adverse	adverse	JJ
cord-028530-hpgrbhkl	19	27	effects	effect	NNS
cord-028530-hpgrbhkl	19	28	to	to	IN
cord-028530-hpgrbhkl	19	29	this	this	DT
cord-028530-hpgrbhkl	19	30	new	new	JJ
cord-028530-hpgrbhkl	19	31	therapeutic	therapeutic	JJ
cord-028530-hpgrbhkl	19	32	scenario	scenario	NN
cord-028530-hpgrbhkl	19	33	.	.	.
cord-028530-hpgrbhkl	20	1	The	the	DT
cord-028530-hpgrbhkl	20	2	following	following	JJ
cord-028530-hpgrbhkl	20	3	considerations	consideration	NNS
cord-028530-hpgrbhkl	20	4	aim	aim	VBP
cord-028530-hpgrbhkl	20	5	to	to	TO
cord-028530-hpgrbhkl	20	6	optimize	optimize	VB
cord-028530-hpgrbhkl	20	7	the	the	DT
cord-028530-hpgrbhkl	20	8	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	20	9	treatment	treatment	NN
cord-028530-hpgrbhkl	20	10	of	of	IN
cord-028530-hpgrbhkl	20	11	COVID-19	covid-19	NN
cord-028530-hpgrbhkl	20	12	:	:	:
cord-028530-hpgrbhkl	20	13	-When	-When	NFP
cord-028530-hpgrbhkl	20	14	the	the	DT
cord-028530-hpgrbhkl	20	15	doctor	doctor	NN
cord-028530-hpgrbhkl	20	16	considers	consider	VBZ
cord-028530-hpgrbhkl	20	17	that	that	IN
cord-028530-hpgrbhkl	20	18	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	20	19	can	can	MD
cord-028530-hpgrbhkl	20	20	be	be	VB
cord-028530-hpgrbhkl	20	21	useful	useful	JJ
cord-028530-hpgrbhkl	20	22	,	,	,
cord-028530-hpgrbhkl	20	23	it	-PRON-	PRP
cord-028530-hpgrbhkl	20	24	should	should	MD
cord-028530-hpgrbhkl	20	25	be	be	VB
cord-028530-hpgrbhkl	20	26	initiated	initiate	VBN
cord-028530-hpgrbhkl	20	27	as	as	RB
cord-028530-hpgrbhkl	20	28	early	early	RB
cord-028530-hpgrbhkl	20	29	as	as	IN
cord-028530-hpgrbhkl	20	30	possible	possible	JJ
cord-028530-hpgrbhkl	20	31	after	after	IN
cord-028530-hpgrbhkl	20	32	diagnosing	diagnose	VBG
cord-028530-hpgrbhkl	20	33	the	the	DT
cord-028530-hpgrbhkl	20	34	infection	infection	NN
cord-028530-hpgrbhkl	20	35	,	,	,
cord-028530-hpgrbhkl	20	36	due	due	IN
cord-028530-hpgrbhkl	20	37	to	to	IN
cord-028530-hpgrbhkl	20	38	the	the	DT
cord-028530-hpgrbhkl	20	39	decrease	decrease	NN
cord-028530-hpgrbhkl	20	40	in	in	IN
cord-028530-hpgrbhkl	20	41	viral	viral	JJ
cord-028530-hpgrbhkl	20	42	replication	replication	NN
cord-028530-hpgrbhkl	20	43	and	and	CC
cord-028530-hpgrbhkl	20	44	dissemination	dissemination	NN
cord-028530-hpgrbhkl	20	45	demonstrated	demonstrate	VBN
cord-028530-hpgrbhkl	20	46	in	in	IN
cord-028530-hpgrbhkl	20	47	vitro	vitro	FW
cord-028530-hpgrbhkl	20	48	and	and	CC
cord-028530-hpgrbhkl	20	49	in	in	IN
cord-028530-hpgrbhkl	20	50	vivo	vivo	NNP
cord-028530-hpgrbhkl	20	51	1	1	CD
cord-028530-hpgrbhkl	20	52	.	.	.
cord-028530-hpgrbhkl	21	1	-Using	-use	VBG
cord-028530-hpgrbhkl	21	2	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	21	3	in	in	IN
cord-028530-hpgrbhkl	21	4	an	an	DT
cord-028530-hpgrbhkl	21	5	acute	acute	JJ
cord-028530-hpgrbhkl	21	6	treatment	treatment	NN
cord-028530-hpgrbhkl	21	7	(	(	-LRB-
cord-028530-hpgrbhkl	21	8	5	5	CD
cord-028530-hpgrbhkl	21	9	days	day	NNS
cord-028530-hpgrbhkl	21	10	)	)	-RRB-
cord-028530-hpgrbhkl	21	11	,	,	,
cord-028530-hpgrbhkl	21	12	with	with	IN
cord-028530-hpgrbhkl	21	13	loading	loading	NN
cord-028530-hpgrbhkl	21	14	dose	dose	NN
cord-028530-hpgrbhkl	21	15	(	(	-LRB-
cord-028530-hpgrbhkl	21	16	400	400	CD
cord-028530-hpgrbhkl	21	17	░	░	NNP
cord-028530-hpgrbhkl	21	18	mg	mg	NNP
cord-028530-hpgrbhkl	21	19	/	/	SYM
cord-028530-hpgrbhkl	21	20	every	every	DT
cord-028530-hpgrbhkl	21	21	12	12	CD
cord-028530-hpgrbhkl	21	22	░	░	NNP
cord-028530-hpgrbhkl	21	23	h	h	NN
cord-028530-hpgrbhkl	21	24	)	)	-RRB-
cord-028530-hpgrbhkl	21	25	the	the	DT
cord-028530-hpgrbhkl	21	26	first	first	JJ
cord-028530-hpgrbhkl	21	27	day	day	NN
cord-028530-hpgrbhkl	21	28	and	and	CC
cord-028530-hpgrbhkl	21	29	4	4	CD
cord-028530-hpgrbhkl	21	30	days	day	NNS
cord-028530-hpgrbhkl	21	31	of	of	IN
cord-028530-hpgrbhkl	21	32	maintenance	maintenance	NN
cord-028530-hpgrbhkl	21	33	(	(	-LRB-
cord-028530-hpgrbhkl	21	34	200	200	CD
cord-028530-hpgrbhkl	21	35	░	░	NNP
cord-028530-hpgrbhkl	21	36	mg	mg	NNP
cord-028530-hpgrbhkl	21	37	/	/	:
cord-028530-hpgrbhkl	21	38	every	every	DT
cord-028530-hpgrbhkl	21	39	12	12	CD
cord-028530-hpgrbhkl	21	40	░	░	NNP
cord-028530-hpgrbhkl	21	41	h	h	NN
cord-028530-hpgrbhkl	21	42	)	)	-RRB-
cord-028530-hpgrbhkl	21	43	,	,	,
cord-028530-hpgrbhkl	21	44	after	after	IN
cord-028530-hpgrbhkl	21	45	requesting	request	VBG
cord-028530-hpgrbhkl	21	46	an	an	DT
cord-028530-hpgrbhkl	21	47	informed	informed	JJ
cord-028530-hpgrbhkl	21	48	medical	medical	JJ
cord-028530-hpgrbhkl	21	49	consent	consent	NN
cord-028530-hpgrbhkl	21	50	(	(	-LRB-
cord-028530-hpgrbhkl	21	51	with	with	IN
cord-028530-hpgrbhkl	21	52	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	21	53	being	be	VBG
cord-028530-hpgrbhkl	21	54	an	an	DT
cord-028530-hpgrbhkl	21	55	indication	indication	NN
cord-028530-hpgrbhkl	21	56	not	not	RB
cord-028530-hpgrbhkl	21	57	contemplated	contemplate	VBN
cord-028530-hpgrbhkl	21	58	in	in	IN
cord-028530-hpgrbhkl	21	59	the	the	DT
cord-028530-hpgrbhkl	21	60	SmPC	smpc	NN
cord-028530-hpgrbhkl	21	61	)	)	-RRB-
cord-028530-hpgrbhkl	21	62	.	.	.
cord-028530-hpgrbhkl	22	1	-Minimize	-minimize	DT
cord-028530-hpgrbhkl	22	2	the	the	DT
cord-028530-hpgrbhkl	22	3	risk	risk	NN
cord-028530-hpgrbhkl	22	4	of	of	IN
cord-028530-hpgrbhkl	22	5	prolonged	prolonged	JJ
cord-028530-hpgrbhkl	22	6	QTc	qtc	NN
cord-028530-hpgrbhkl	22	7	.	.	.
cord-028530-hpgrbhkl	23	1	For	for	IN
cord-028530-hpgrbhkl	23	2	this	this	DT
cord-028530-hpgrbhkl	23	3	,	,	,
cord-028530-hpgrbhkl	23	4	a	a	DT
cord-028530-hpgrbhkl	23	5	baseline	baseline	JJ
cord-028530-hpgrbhkl	23	6	electrocardiogram	electrocardiogram	NN
cord-028530-hpgrbhkl	23	7	(	(	-LRB-
cord-028530-hpgrbhkl	23	8	ECG	ECG	NNP
cord-028530-hpgrbhkl	23	9	)	)	-RRB-
cord-028530-hpgrbhkl	23	10	must	must	MD
cord-028530-hpgrbhkl	23	11	be	be	VB
cord-028530-hpgrbhkl	23	12	performed	perform	VBN
cord-028530-hpgrbhkl	23	13	prior	prior	RB
cord-028530-hpgrbhkl	23	14	to	to	IN
cord-028530-hpgrbhkl	23	15	the	the	DT
cord-028530-hpgrbhkl	23	16	start	start	NN
cord-028530-hpgrbhkl	23	17	of	of	IN
cord-028530-hpgrbhkl	23	18	treatment	treatment	NN
cord-028530-hpgrbhkl	23	19	.	.	.
cord-028530-hpgrbhkl	24	1	If	if	IN
cord-028530-hpgrbhkl	24	2	the	the	DT
cord-028530-hpgrbhkl	24	3	QTc	qtc	NN
cord-028530-hpgrbhkl	24	4	is	be	VBZ
cord-028530-hpgrbhkl	24	5	greater	great	JJR
cord-028530-hpgrbhkl	24	6	than	than	IN
cord-028530-hpgrbhkl	24	7	or	or	CC
cord-028530-hpgrbhkl	24	8	equal	equal	JJ
cord-028530-hpgrbhkl	24	9	to	to	IN
cord-028530-hpgrbhkl	24	10	500	500	CD
cord-028530-hpgrbhkl	24	11	░	░	NNP
cord-028530-hpgrbhkl	24	12	ms	ms	NNP
cord-028530-hpgrbhkl	24	13	,	,	,
cord-028530-hpgrbhkl	24	14	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	24	15	should	should	MD
cord-028530-hpgrbhkl	24	16	not	not	RB
cord-028530-hpgrbhkl	24	17	be	be	VB
cord-028530-hpgrbhkl	24	18	started	start	VBN
cord-028530-hpgrbhkl	24	19	.	.	.
cord-028530-hpgrbhkl	25	1	If	if	IN
cord-028530-hpgrbhkl	25	2	the	the	DT
cord-028530-hpgrbhkl	25	3	QTc	qtc	NN
cord-028530-hpgrbhkl	25	4	is	be	VBZ
cord-028530-hpgrbhkl	25	5	less	less	JJR
cord-028530-hpgrbhkl	25	6	than	than	IN
cord-028530-hpgrbhkl	25	7	470	470	CD
cord-028530-hpgrbhkl	25	8	░	░	NNP
cord-028530-hpgrbhkl	25	9	ms	ms	NNP
cord-028530-hpgrbhkl	25	10	in	in	IN
cord-028530-hpgrbhkl	25	11	men	man	NNS
cord-028530-hpgrbhkl	25	12	or	or	CC
cord-028530-hpgrbhkl	25	13	less	less	JJR
cord-028530-hpgrbhkl	25	14	than	than	IN
cord-028530-hpgrbhkl	25	15	480	480	CD
cord-028530-hpgrbhkl	25	16	░	░	NNP
cord-028530-hpgrbhkl	25	17	ms	ms	NNP
cord-028530-hpgrbhkl	25	18	in	in	IN
cord-028530-hpgrbhkl	25	19	women	woman	NNS
cord-028530-hpgrbhkl	25	20	,	,	,
cord-028530-hpgrbhkl	25	21	treatment	treatment	NN
cord-028530-hpgrbhkl	25	22	can	can	MD
cord-028530-hpgrbhkl	25	23	be	be	VB
cord-028530-hpgrbhkl	25	24	initiated	initiate	VBN
cord-028530-hpgrbhkl	25	25	,	,	,
cord-028530-hpgrbhkl	25	26	repeating	repeat	VBG
cord-028530-hpgrbhkl	25	27	the	the	DT
cord-028530-hpgrbhkl	25	28	ECG	ECG	NNP
cord-028530-hpgrbhkl	25	29	in	in	IN
cord-028530-hpgrbhkl	25	30	48	48	CD
cord-028530-hpgrbhkl	25	31	░	░	NNP
cord-028530-hpgrbhkl	25	32	h	h	NNP
cord-028530-hpgrbhkl	25	33	.	.	.
cord-028530-hpgrbhkl	26	1	If	if	IN
cord-028530-hpgrbhkl	26	2	the	the	DT
cord-028530-hpgrbhkl	26	3	QTc	qtc	NN
cord-028530-hpgrbhkl	26	4	is	be	VBZ
cord-028530-hpgrbhkl	26	5	greater	great	JJR
cord-028530-hpgrbhkl	26	6	than	than	IN
cord-028530-hpgrbhkl	26	7	or	or	CC
cord-028530-hpgrbhkl	26	8	equal	equal	JJ
cord-028530-hpgrbhkl	26	9	to	to	IN
cord-028530-hpgrbhkl	26	10	500	500	CD
cord-028530-hpgrbhkl	26	11	░	░	NNP
cord-028530-hpgrbhkl	26	12	ms	ms	NNP
cord-028530-hpgrbhkl	26	13	or	or	CC
cord-028530-hpgrbhkl	26	14	an	an	DT
cord-028530-hpgrbhkl	26	15	increase	increase	NN
cord-028530-hpgrbhkl	26	16	greater	great	JJR
cord-028530-hpgrbhkl	26	17	than	than	IN
cord-028530-hpgrbhkl	26	18	or	or	CC
cord-028530-hpgrbhkl	26	19	equal	equal	JJ
cord-028530-hpgrbhkl	26	20	to	to	IN
cord-028530-hpgrbhkl	26	21	60	60	CD
cord-028530-hpgrbhkl	26	22	░	░	NNP
cord-028530-hpgrbhkl	26	23	ms	ms	NNP
cord-028530-hpgrbhkl	26	24	is	be	VBZ
cord-028530-hpgrbhkl	26	25	observed	observe	VBN
cord-028530-hpgrbhkl	26	26	,	,	,
cord-028530-hpgrbhkl	26	27	treatment	treatment	NN
cord-028530-hpgrbhkl	26	28	should	should	MD
cord-028530-hpgrbhkl	26	29	be	be	VB
cord-028530-hpgrbhkl	26	30	discontinued	discontinue	VBN
cord-028530-hpgrbhkl	26	31	4	4	CD
cord-028530-hpgrbhkl	26	32	.	.	.
cord-028530-hpgrbhkl	27	1	-Avoid	-Avoid	:
cord-028530-hpgrbhkl	27	2	or	or	CC
cord-028530-hpgrbhkl	27	3	discontinue	discontinue	VB
cord-028530-hpgrbhkl	27	4	the	the	DT
cord-028530-hpgrbhkl	27	5	simultaneous	simultaneous	JJ
cord-028530-hpgrbhkl	27	6	use	use	NN
cord-028530-hpgrbhkl	27	7	of	of	IN
cord-028530-hpgrbhkl	27	8	drugs	drug	NNS
cord-028530-hpgrbhkl	27	9	that	that	WDT
cord-028530-hpgrbhkl	27	10	prolong	prolong	VBP
cord-028530-hpgrbhkl	27	11	the	the	DT
cord-028530-hpgrbhkl	27	12	QTc	QTc	NNS
cord-028530-hpgrbhkl	27	13	,	,	,
cord-028530-hpgrbhkl	27	14	particularly	particularly	RB
cord-028530-hpgrbhkl	27	15	azithromycin	azithromycin	NNP
cord-028530-hpgrbhkl	27	16	,	,	,
cord-028530-hpgrbhkl	27	17	clarithromycin	clarithromycin	NNP
cord-028530-hpgrbhkl	27	18	,	,	,
cord-028530-hpgrbhkl	27	19	levofloxacin	levofloxacin	NNP
cord-028530-hpgrbhkl	27	20	,	,	,
cord-028530-hpgrbhkl	27	21	moxifloxacin	moxifloxacin	NNS
cord-028530-hpgrbhkl	27	22	,	,	,
cord-028530-hpgrbhkl	27	23	ciprofloxacin	ciprofloxacin	NN
cord-028530-hpgrbhkl	27	24	,	,	,
cord-028530-hpgrbhkl	27	25	haloperidol	haloperidol	NNP
cord-028530-hpgrbhkl	27	26	,	,	,
cord-028530-hpgrbhkl	27	27	quetiapine	quetiapine	NNP
cord-028530-hpgrbhkl	27	28	,	,	,
cord-028530-hpgrbhkl	27	29	risperidone	risperidone	NN
cord-028530-hpgrbhkl	27	30	,	,	,
cord-028530-hpgrbhkl	27	31	domperidone	domperidone	NNP
cord-028530-hpgrbhkl	27	32	and	and	CC
cord-028530-hpgrbhkl	27	33	ondansetron	ondansetron	NN
cord-028530-hpgrbhkl	27	34	,	,	,
cord-028530-hpgrbhkl	27	35	among	among	IN
cord-028530-hpgrbhkl	27	36	others	other	NNS
cord-028530-hpgrbhkl	27	37	4,5	4,5	CD
cord-028530-hpgrbhkl	27	38	.	.	.
cord-028530-hpgrbhkl	28	1	-Keep	-Keep	.
cord-028530-hpgrbhkl	29	1	a	a	DT
cord-028530-hpgrbhkl	29	2	close	close	JJ
cord-028530-hpgrbhkl	29	3	watch	watch	NN
cord-028530-hpgrbhkl	29	4	on	on	IN
cord-028530-hpgrbhkl	29	5	potassium	potassium	NN
cord-028530-hpgrbhkl	29	6	,	,	,
cord-028530-hpgrbhkl	29	7	calcium	calcium	NN
cord-028530-hpgrbhkl	29	8	and	and	CC
cord-028530-hpgrbhkl	29	9	magnesium	magnesium	NN
cord-028530-hpgrbhkl	29	10	levels	level	NNS
cord-028530-hpgrbhkl	29	11	due	due	IN
cord-028530-hpgrbhkl	29	12	to	to	IN
cord-028530-hpgrbhkl	29	13	their	-PRON-	PRP$
cord-028530-hpgrbhkl	29	14	arrhythmogenic	arrhythmogenic	JJ
cord-028530-hpgrbhkl	29	15	potential	potential	NN
cord-028530-hpgrbhkl	29	16	,	,	,
cord-028530-hpgrbhkl	29	17	as	as	RB
cord-028530-hpgrbhkl	29	18	well	well	RB
cord-028530-hpgrbhkl	29	19	as	as	IN
cord-028530-hpgrbhkl	29	20	glycemia	glycemia	NN
cord-028530-hpgrbhkl	29	21	in	in	IN
cord-028530-hpgrbhkl	29	22	patients	patient	NNS
cord-028530-hpgrbhkl	29	23	with	with	IN
cord-028530-hpgrbhkl	29	24	diabetes	diabete	NNS
cord-028530-hpgrbhkl	29	25	due	due	IN
cord-028530-hpgrbhkl	29	26	to	to	IN
cord-028530-hpgrbhkl	29	27	the	the	DT
cord-028530-hpgrbhkl	29	28	risk	risk	NN
cord-028530-hpgrbhkl	29	29	of	of	IN
cord-028530-hpgrbhkl	29	30	hypoglycemia	hypoglycemia	NN
cord-028530-hpgrbhkl	29	31	4	4	CD
cord-028530-hpgrbhkl	29	32	.	.	.
cord-028530-hpgrbhkl	30	1	-Consider	-Consider	:
cord-028530-hpgrbhkl	30	2	not	not	RB
cord-028530-hpgrbhkl	30	3	administering	administer	VBG
cord-028530-hpgrbhkl	30	4	or	or	CC
cord-028530-hpgrbhkl	30	5	discontinuing	discontinue	VBG
cord-028530-hpgrbhkl	30	6	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	30	7	in	in	IN
cord-028530-hpgrbhkl	30	8	advanced	advanced	JJ
cord-028530-hpgrbhkl	30	9	stages	stage	NNS
cord-028530-hpgrbhkl	30	10	of	of	IN
cord-028530-hpgrbhkl	30	11	infection	infection	NN
cord-028530-hpgrbhkl	30	12	due	due	IN
cord-028530-hpgrbhkl	30	13	to	to	IN
cord-028530-hpgrbhkl	30	14	the	the	DT
cord-028530-hpgrbhkl	30	15	possibility	possibility	NN
cord-028530-hpgrbhkl	30	16	of	of	IN
cord-028530-hpgrbhkl	30	17	a	a	DT
cord-028530-hpgrbhkl	30	18	COVID-19-induced	COVID-19-induced	NNP
cord-028530-hpgrbhkl	30	19	myocarditis	myocarditis	NN
cord-028530-hpgrbhkl	30	20	3,5	3,5	CD
cord-028530-hpgrbhkl	30	21	.	.	.
cord-028530-hpgrbhkl	31	1	-It	-It	:
cord-028530-hpgrbhkl	31	2	is	be	VBZ
cord-028530-hpgrbhkl	31	3	not	not	RB
cord-028530-hpgrbhkl	31	4	necessary	necessary	JJ
cord-028530-hpgrbhkl	31	5	to	to	TO
cord-028530-hpgrbhkl	31	6	adjust	adjust	VB
cord-028530-hpgrbhkl	31	7	the	the	DT
cord-028530-hpgrbhkl	31	8	dose	dose	NN
cord-028530-hpgrbhkl	31	9	based	base	VBN
cord-028530-hpgrbhkl	31	10	on	on	IN
cord-028530-hpgrbhkl	31	11	renal	renal	JJ
cord-028530-hpgrbhkl	31	12	or	or	CC
cord-028530-hpgrbhkl	31	13	hepatic	hepatic	JJ
cord-028530-hpgrbhkl	31	14	function	function	NN
cord-028530-hpgrbhkl	31	15	,	,	,
cord-028530-hpgrbhkl	31	16	nor	nor	CC
cord-028530-hpgrbhkl	31	17	does	do	VBZ
cord-028530-hpgrbhkl	31	18	it	-PRON-	PRP
cord-028530-hpgrbhkl	31	19	require	require	VB
cord-028530-hpgrbhkl	31	20	ophthalmological	ophthalmological	JJ
cord-028530-hpgrbhkl	31	21	control	control	NN
cord-028530-hpgrbhkl	31	22	before	before	IN
cord-028530-hpgrbhkl	31	23	or	or	CC
cord-028530-hpgrbhkl	31	24	after	after	IN
cord-028530-hpgrbhkl	31	25	treatment	treatment	NN
cord-028530-hpgrbhkl	31	26	6	6	CD
cord-028530-hpgrbhkl	31	27	.	.	.
cord-028530-hpgrbhkl	32	1	-Pending	-pende	VBG
cord-028530-hpgrbhkl	32	2	the	the	DT
cord-028530-hpgrbhkl	32	3	result	result	NN
cord-028530-hpgrbhkl	32	4	of	of	IN
cord-028530-hpgrbhkl	32	5	several	several	JJ
cord-028530-hpgrbhkl	32	6	active	active	JJ
cord-028530-hpgrbhkl	32	7	studies	study	NNS
cord-028530-hpgrbhkl	32	8	,	,	,
cord-028530-hpgrbhkl	32	9	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	32	10	should	should	MD
cord-028530-hpgrbhkl	32	11	not	not	RB
cord-028530-hpgrbhkl	32	12	be	be	VB
cord-028530-hpgrbhkl	32	13	indicated	indicate	VBN
cord-028530-hpgrbhkl	32	14	prophylactically	prophylactically	RB
cord-028530-hpgrbhkl	32	15	as	as	IN
cord-028530-hpgrbhkl	32	16	there	there	EX
cord-028530-hpgrbhkl	32	17	is	be	VBZ
cord-028530-hpgrbhkl	32	18	no	no	DT
cord-028530-hpgrbhkl	32	19	evidence	evidence	NN
cord-028530-hpgrbhkl	32	20	to	to	TO
cord-028530-hpgrbhkl	32	21	support	support	VB
cord-028530-hpgrbhkl	32	22	its	-PRON-	PRP$
cord-028530-hpgrbhkl	32	23	preventive	preventive	JJ
cord-028530-hpgrbhkl	32	24	use	use	NN
cord-028530-hpgrbhkl	32	25	or	or	CC
cord-028530-hpgrbhkl	32	26	postexposure	postexposure	NN
cord-028530-hpgrbhkl	32	27	to	to	TO
cord-028530-hpgrbhkl	32	28	avoid	avoid	VB
cord-028530-hpgrbhkl	32	29	COVID-19	covid-19	JJ
cord-028530-hpgrbhkl	32	30	infection	infection	NN
cord-028530-hpgrbhkl	32	31	.	.	.
cord-028530-hpgrbhkl	33	1	In	in	IN
cord-028530-hpgrbhkl	33	2	short	short	JJ
cord-028530-hpgrbhkl	33	3	,	,	,
cord-028530-hpgrbhkl	33	4	when	when	WRB
cord-028530-hpgrbhkl	33	5	prescribing	prescribe	VBG
cord-028530-hpgrbhkl	33	6	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	33	7	in	in	IN
cord-028530-hpgrbhkl	33	8	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	33	9	,	,	,
cord-028530-hpgrbhkl	33	10	different	different	JJ
cord-028530-hpgrbhkl	33	11	precautions	precaution	NNS
cord-028530-hpgrbhkl	33	12	should	should	MD
cord-028530-hpgrbhkl	33	13	be	be	VB
cord-028530-hpgrbhkl	33	14	taken	take	VBN
cord-028530-hpgrbhkl	33	15	from	from	IN
cord-028530-hpgrbhkl	33	16	those	those	DT
cord-028530-hpgrbhkl	33	17	currently	currently	RB
cord-028530-hpgrbhkl	33	18	considered	consider	VBN
cord-028530-hpgrbhkl	33	19	for	for	IN
cord-028530-hpgrbhkl	33	20	SLE	SLE	NNP
cord-028530-hpgrbhkl	33	21	patients	patient	NNS
cord-028530-hpgrbhkl	33	22	.	.	.
cord-028530-hpgrbhkl	34	1	It	-PRON-	PRP
cord-028530-hpgrbhkl	34	2	should	should	MD
cord-028530-hpgrbhkl	34	3	be	be	VB
cord-028530-hpgrbhkl	34	4	indicated	indicate	VBN
cord-028530-hpgrbhkl	34	5	in	in	IN
cord-028530-hpgrbhkl	34	6	its	-PRON-	PRP$
cord-028530-hpgrbhkl	34	7	window	window	NN
cord-028530-hpgrbhkl	34	8	of	of	IN
cord-028530-hpgrbhkl	34	9	opportunity	opportunity	NN
cord-028530-hpgrbhkl	34	10	and	and	CC
cord-028530-hpgrbhkl	34	11	consider	consider	VB
cord-028530-hpgrbhkl	34	12	the	the	DT
cord-028530-hpgrbhkl	34	13	existing	exist	VBG
cord-028530-hpgrbhkl	34	14	multifactorial	multifactorial	JJ
cord-028530-hpgrbhkl	34	15	myocardial	myocardial	JJ
cord-028530-hpgrbhkl	34	16	involvement	involvement	NN
cord-028530-hpgrbhkl	34	17	,	,	,
cord-028530-hpgrbhkl	34	18	seeking	seek	VBG
cord-028530-hpgrbhkl	34	19	to	to	TO
cord-028530-hpgrbhkl	34	20	avoid	avoid	VB
cord-028530-hpgrbhkl	34	21	cardiovascular	cardiovascular	JJ
cord-028530-hpgrbhkl	34	22	adverse	adverse	JJ
cord-028530-hpgrbhkl	34	23	effects	effect	NNS
cord-028530-hpgrbhkl	34	24	.	.	.
cord-028530-hpgrbhkl	35	1	The	the	DT
cord-028530-hpgrbhkl	35	2	results	result	NNS
cord-028530-hpgrbhkl	35	3	of	of	IN
cord-028530-hpgrbhkl	35	4	different	different	JJ
cord-028530-hpgrbhkl	35	5	controlled	control	VBN
cord-028530-hpgrbhkl	35	6	and	and	CC
cord-028530-hpgrbhkl	35	7	J	J	NNP
cord-028530-hpgrbhkl	35	8	o	o	NN
cord-028530-hpgrbhkl	35	9	u	u	NN
cord-028530-hpgrbhkl	35	10	r	r	NN
cord-028530-hpgrbhkl	35	11	n	n	NN
cord-028530-hpgrbhkl	35	12	a	a	DT
cord-028530-hpgrbhkl	35	13	l	l	NN
cord-028530-hpgrbhkl	35	14	P	p	NN
cord-028530-hpgrbhkl	35	15	r	r	NN
cord-028530-hpgrbhkl	35	16	e	e	NN
cord-028530-hpgrbhkl	35	17	-p	-p	NN
cord-028530-hpgrbhkl	35	18	r	r	NN
cord-028530-hpgrbhkl	35	19	o	o	NN
cord-028530-hpgrbhkl	35	20	o	o	NN
cord-028530-hpgrbhkl	35	21	f	f	NN
cord-028530-hpgrbhkl	35	22	randomized	randomized	JJ
cord-028530-hpgrbhkl	35	23	studies	study	NNS
cord-028530-hpgrbhkl	35	24	that	that	WDT
cord-028530-hpgrbhkl	35	25	confirm	confirm	VBP
cord-028530-hpgrbhkl	35	26	or	or	CC
cord-028530-hpgrbhkl	35	27	refute	refute	VB
cord-028530-hpgrbhkl	35	28	the	the	DT
cord-028530-hpgrbhkl	35	29	usefulness	usefulness	NN
cord-028530-hpgrbhkl	35	30	of	of	IN
cord-028530-hpgrbhkl	35	31	HCQ	HCQ	NNP
cord-028530-hpgrbhkl	35	32	in	in	IN
cord-028530-hpgrbhkl	35	33	the	the	DT
cord-028530-hpgrbhkl	35	34	treatment	treatment	NN
cord-028530-hpgrbhkl	35	35	of	of	IN
cord-028530-hpgrbhkl	35	36	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	35	37	will	will	MD
cord-028530-hpgrbhkl	35	38	contribute	contribute	VB
cord-028530-hpgrbhkl	35	39	to	to	TO
cord-028530-hpgrbhkl	35	40	define	define	VB
cord-028530-hpgrbhkl	35	41	its	-PRON-	PRP$
cord-028530-hpgrbhkl	35	42	role	role	NN
cord-028530-hpgrbhkl	35	43	in	in	IN
cord-028530-hpgrbhkl	35	44	this	this	DT
cord-028530-hpgrbhkl	35	45	clinical	clinical	JJ
cord-028530-hpgrbhkl	35	46	setting	setting	NN
cord-028530-hpgrbhkl	35	47	.	.	.
cord-028530-hpgrbhkl	36	1	The	the	DT
cord-028530-hpgrbhkl	36	2	authors	author	NNS
cord-028530-hpgrbhkl	36	3	declare	declare	VBP
cord-028530-hpgrbhkl	36	4	that	that	IN
cord-028530-hpgrbhkl	36	5	they	-PRON-	PRP
cord-028530-hpgrbhkl	36	6	have	have	VBP
cord-028530-hpgrbhkl	36	7	not	not	RB
cord-028530-hpgrbhkl	36	8	received	receive	VBN
cord-028530-hpgrbhkl	36	9	funding	funding	NN
cord-028530-hpgrbhkl	36	10	to	to	TO
cord-028530-hpgrbhkl	36	11	carry	carry	VB
cord-028530-hpgrbhkl	36	12	out	out	RP
cord-028530-hpgrbhkl	36	13	this	this	DT
cord-028530-hpgrbhkl	36	14	study	study	NN
cord-028530-hpgrbhkl	36	15	.	.	.
cord-028530-hpgrbhkl	37	1	Uso	Uso	NNP
cord-028530-hpgrbhkl	37	2	de	de	IN
cord-028530-hpgrbhkl	37	3	antipalúdicos	antipalúdicos	NNP
cord-028530-hpgrbhkl	37	4	en	en	IN
cord-028530-hpgrbhkl	37	5	el	el	NNP
cord-028530-hpgrbhkl	37	6	tratamiento	tratamiento	NNP
cord-028530-hpgrbhkl	37	7	del	del	NNP
cord-028530-hpgrbhkl	38	1	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	38	2	:	:	:
cord-028530-hpgrbhkl	38	3	una	una	NNP
cord-028530-hpgrbhkl	38	4	ventana	ventana	NNP
cord-028530-hpgrbhkl	38	5	de	de	NNP
cord-028530-hpgrbhkl	38	6	oportunidad	oportunidad	NNP
cord-028530-hpgrbhkl	38	7	?	?	.
cord-028530-hpgrbhkl	39	1	Antimalarialinduced	antimalarialinduced	JJ
cord-028530-hpgrbhkl	39	2	cardiomyopathy	cardiomyopathy	NN
cord-028530-hpgrbhkl	39	3	:	:	:
cord-028530-hpgrbhkl	39	4	a	a	DT
cord-028530-hpgrbhkl	39	5	systematic	systematic	JJ
cord-028530-hpgrbhkl	39	6	review	review	NN
cord-028530-hpgrbhkl	39	7	of	of	IN
cord-028530-hpgrbhkl	39	8	the	the	DT
cord-028530-hpgrbhkl	39	9	literature	literature	NN
cord-028530-hpgrbhkl	39	10	Cardiovascular	cardiovascular	JJ
cord-028530-hpgrbhkl	39	11	complications	complication	NNS
cord-028530-hpgrbhkl	39	12	in	in	IN
cord-028530-hpgrbhkl	39	13	patients	patient	NNS
cord-028530-hpgrbhkl	39	14	with	with	IN
cord-028530-hpgrbhkl	39	15	COVID-19	covid-19	NN
cord-028530-hpgrbhkl	39	16	:	:	:
cord-028530-hpgrbhkl	39	17	consequences	consequence	NNS
cord-028530-hpgrbhkl	39	18	of	of	IN
cord-028530-hpgrbhkl	39	19	viral	viral	JJ
cord-028530-hpgrbhkl	39	20	toxicities	toxicity	NNS
cord-028530-hpgrbhkl	39	21	and	and	CC
cord-028530-hpgrbhkl	39	22	host	host	NN
cord-028530-hpgrbhkl	39	23	immune	immune	JJ
cord-028530-hpgrbhkl	39	24	response	response	NN
cord-028530-hpgrbhkl	39	25	Guidance	guidance	NN
cord-028530-hpgrbhkl	39	26	of	of	IN
cord-028530-hpgrbhkl	39	27	minimizing	minimize	VBG
cord-028530-hpgrbhkl	39	28	risk	risk	NN
cord-028530-hpgrbhkl	39	29	of	of	IN
cord-028530-hpgrbhkl	39	30	druginduced	druginduced	JJ
cord-028530-hpgrbhkl	39	31	ventricular	ventricular	JJ
cord-028530-hpgrbhkl	39	32	arrhytmia	arrhytmia	NN
cord-028530-hpgrbhkl	39	33	during	during	IN
cord-028530-hpgrbhkl	39	34	treatment	treatment	NN
cord-028530-hpgrbhkl	39	35	of	of	IN
cord-028530-hpgrbhkl	39	36	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	39	37	:	:	:
cord-028530-hpgrbhkl	39	38	a	a	DT
cord-028530-hpgrbhkl	39	39	statement	statement	NN
cord-028530-hpgrbhkl	39	40	from	from	IN
cord-028530-hpgrbhkl	39	41	the	the	DT
cord-028530-hpgrbhkl	39	42	Canadian	canadian	JJ
cord-028530-hpgrbhkl	39	43	heart	heart	NN
cord-028530-hpgrbhkl	39	44	rhythm	rhythm	NN
cord-028530-hpgrbhkl	39	45	Society	Society	NNP
cord-028530-hpgrbhkl	39	46	Description	Description	NNP
cord-028530-hpgrbhkl	39	47	and	and	CC
cord-028530-hpgrbhkl	39	48	proposed	propose	VBN
cord-028530-hpgrbhkl	39	49	management	management	NN
cord-028530-hpgrbhkl	39	50	of	of	IN
cord-028530-hpgrbhkl	39	51	the	the	DT
cord-028530-hpgrbhkl	39	52	acute	acute	JJ
cord-028530-hpgrbhkl	39	53	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	39	54	cardiovascular	cardiovascular	JJ
cord-028530-hpgrbhkl	39	55	syndrome	syndrome	NN
cord-028530-hpgrbhkl	39	56	COVID-19	COVID-19	NNP
cord-028530-hpgrbhkl	39	57	and	and	CC
cord-028530-hpgrbhkl	39	58	chloroquine	chloroquine	NNP
cord-028530-hpgrbhkl	39	59	/	/	SYM
cord-028530-hpgrbhkl	39	60	hydroxychloroquine	hydroxychloroquine	NN
cord-028530-hpgrbhkl	39	61	:	:	:
cord-028530-hpgrbhkl	39	62	is	be	VBZ
cord-028530-hpgrbhkl	39	63	there	there	EX
cord-028530-hpgrbhkl	39	64	ophthalmological	ophthalmological	JJ
cord-028530-hpgrbhkl	39	65	concern	concern	NN
cord-028530-hpgrbhkl	39	66	?	?	.